202 related articles for article (PubMed ID: 23539745)
1. Alternative mutational pathways to intermediate resistance to vancomycin in methicillin-resistant Staphylococcus aureus.
Vidaillac C; Gardete S; Tewhey R; Sakoulas G; Kaatz GW; Rose WE; Tomasz A; Rybak MJ
J Infect Dis; 2013 Jul; 208(1):67-74. PubMed ID: 23539745
[TBL] [Abstract][Full Text] [Related]
2. Genetic pathway in acquisition and loss of vancomycin resistance in a methicillin resistant Staphylococcus aureus (MRSA) strain of clonal type USA300.
Gardete S; Kim C; Hartmann BM; Mwangi M; Roux CM; Dunman PM; Chambers HF; Tomasz A
PLoS Pathog; 2012 Feb; 8(2):e1002505. PubMed ID: 22319446
[TBL] [Abstract][Full Text] [Related]
3. Dalbavancin exposure in vitro selects for dalbavancin-non-susceptible and vancomycin-intermediate strains of methicillin-resistant Staphylococcus aureus.
Werth BJ; Ashford NK; Penewit K; Waalkes A; Holmes EA; Ross DH; Shen T; Hines KM; Salipante SJ; Xu L
Clin Microbiol Infect; 2021 Jun; 27(6):910.e1-910.e8. PubMed ID: 32866650
[TBL] [Abstract][Full Text] [Related]
4. Association of mprF mutations with cross-resistance to daptomycin and vancomycin in methicillin-resistant Staphylococcus aureus (MRSA).
Thitiananpakorn K; Aiba Y; Tan XE; Watanabe S; Kiga K; Sato'o Y; Boonsiri T; Li FY; Sasahara T; Taki Y; Azam AH; Zhang Y; Cui L
Sci Rep; 2020 Sep; 10(1):16107. PubMed ID: 32999359
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the Presence and Characterization of Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Level Resistance Among Bloodstream Isolates of Methicillin-Resistant
Ozmen Capin BB; Tekeli A; Karahan ZC
Microb Drug Resist; 2020 Mar; 26(3):238-244. PubMed ID: 31545160
[No Abstract] [Full Text] [Related]
6. In vivo development of daptomycin resistance in vancomycin-susceptible methicillin-resistant Staphylococcus aureus severe infections previously treated with glycopeptides.
Capone A; Cafiso V; Campanile F; Parisi G; Mariani B; Petrosillo N; Stefani S
Eur J Clin Microbiol Infect Dis; 2016 Apr; 35(4):625-31. PubMed ID: 26815434
[TBL] [Abstract][Full Text] [Related]
7. Decreased vancomycin susceptibility in Staphylococcus aureus caused by IS256 tempering of WalKR expression.
McEvoy CR; Tsuji B; Gao W; Seemann T; Porter JL; Doig K; Ngo D; Howden BP; Stinear TP
Antimicrob Agents Chemother; 2013 Jul; 57(7):3240-9. PubMed ID: 23629723
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA among methicillin-resistant S. aureus with high vancomycin minimal inhibitory concentrations in Taiwan: A multicenter surveillance study, 2012-2013.
Huang SH; Chen YC; Chuang YC; Chiu SK; Fung CP; Lu PL; Wang LS; Wu TL; Wang JT
J Microbiol Immunol Infect; 2016 Oct; 49(5):701-707. PubMed ID: 26320398
[TBL] [Abstract][Full Text] [Related]
9. Development of an Amplicon Nanopore Sequencing Strategy for Detection of Mutations Conferring Intermediate Resistance to Vancomycin in Staphylococcus aureus Strains.
Moller AG; Petit RA; Davis MH; Read TD
Microbiol Spectr; 2023 Feb; 11(1):e0272822. PubMed ID: 36688645
[TBL] [Abstract][Full Text] [Related]
10. An RpoB mutation confers dual heteroresistance to daptomycin and vancomycin in Staphylococcus aureus.
Cui L; Isii T; Fukuda M; Ochiai T; Neoh HM; Camargo IL; Watanabe Y; Shoji M; Hishinuma T; Hiramatsu K
Antimicrob Agents Chemother; 2010 Dec; 54(12):5222-33. PubMed ID: 20837752
[TBL] [Abstract][Full Text] [Related]
11. Evolution of multidrug resistance during Staphylococcus aureus infection involves mutation of the essential two component regulator WalKR.
Howden BP; McEvoy CR; Allen DL; Chua K; Gao W; Harrison PF; Bell J; Coombs G; Bennett-Wood V; Porter JL; Robins-Browne R; Davies JK; Seemann T; Stinear TP
PLoS Pathog; 2011 Nov; 7(11):e1002359. PubMed ID: 22102812
[TBL] [Abstract][Full Text] [Related]
12. Cervimycin-Resistant Staphylococcus aureus Strains Display Vancomycin-Intermediate Resistant Phenotypes.
Dietrich A; Steffens U; Gajdiss M; Boschert AL; Dröge JK; Szekat C; Sass P; Malik IT; Bornikoel J; Reinke L; Maček B; Franz-Wachtel M; Nieselt K; Harbig T; Scherlach K; Brötz-Oesterhelt H; Hertweck C; Sahl HG; Bierbaum G
Microbiol Spectr; 2022 Oct; 10(5):e0256722. PubMed ID: 36173303
[TBL] [Abstract][Full Text] [Related]
13. The Prevalence of Vancomycin-Intermediate Staphylococcus aureus and Heterogeneous VISA Among Methicillin-Resistant Strains Isolated from Pediatric Population in a Turkish University Hospital.
Mirza HC; Sancak B; Gür D
Microb Drug Resist; 2015 Oct; 21(5):537-44. PubMed ID: 25919019
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of meropenem/piperacillin/tazobactam triple combination therapy against clinical isolates of Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus pseudintermedius and vancomycin-resistant Enterococcus spp.
Yoneda A; Thänert R; Burnham CD; Dantas G
Int J Antimicrob Agents; 2020 Feb; 55(2):105864. PubMed ID: 31870598
[TBL] [Abstract][Full Text] [Related]
15. Telavancin demonstrates activity against methicillin-resistant Staphylococcus aureus isolates with reduced susceptibility to vancomycin, daptomycin, and linezolid in broth microdilution MIC and one-compartment pharmacokinetic/pharmacodynamic models.
Smith JR; Barber KE; Hallesy J; Raut A; Rybak MJ
Antimicrob Agents Chemother; 2015 Sep; 59(9):5529-34. PubMed ID: 26124162
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model.
Zhanel GG; Voth D; Nichol K; Karlowsky JA; Noreddin AM; Hoban DJ
J Antimicrob Chemother; 2009 Aug; 64(2):364-9. PubMed ID: 19454524
[TBL] [Abstract][Full Text] [Related]
17. Role of stop codons in development and loss of vancomycin non-susceptibility in methicillin-resistant Staphylococcus aureus.
Doddangoudar VC; O'Donoghue MM; Chong EY; Tsang DN; Boost MV
J Antimicrob Chemother; 2012 Sep; 67(9):2101-6. PubMed ID: 22643192
[TBL] [Abstract][Full Text] [Related]
18. Emergence of vancomycin-intermediate and -resistant Staphylococcus aureus among methicillin-resistant S. aureus isolated from clinical specimens in the northwest of Iran.
Ghahremani M; Jazani NH; Sharifi Y
J Glob Antimicrob Resist; 2018 Sep; 14():4-9. PubMed ID: 29454049
[TBL] [Abstract][Full Text] [Related]
19. Impact of vancomycin use trend change due to the availability of alternative antibiotics on the prevalence of Staphylococcus aureus with reduced vancomycin susceptibility: a 14-year retrospective study.
Kang YR; Kim SH; Chung DR; Ko JH; Huh K; Cho SY; Kang CI; Peck KR
Antimicrob Resist Infect Control; 2022 Aug; 11(1):101. PubMed ID: 35932086
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus and heterogeneously vancomycin-intermediate S. aureus in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations.
Leonard SN; Rybak MJ
J Antimicrob Chemother; 2009 Jan; 63(1):155-60. PubMed ID: 18984644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
